Immunicum | Innovation in immuno-oncology

Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU

Tweets by @Immunicum

Tweets by Immunicum

Press Releases

Immunicum AB (publ) Publishes the Annual Report for 2019
03 Apr 2020
Immunicum AB (publ) Announces Peter Suenaert to Resume Role as Chief Medical Officer
30 Mar 2020
Notice of Annual General Meeting in Immunicum AB (publ)
27 Mar 2020

See all

Latest Corporate presentation

Årsredovisning 2019 Corporate Presentation February 2020 Complete Topline Data Analysis from Phase II MERECA Trial Quarterly Report Presentation & Business Strategy video - 20 Aug 2019

News

ASCO Post Article / Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
12 Mar 2020
RedEye Fight Cancer Seminar Presentation
10 Mar 2020
Article in BioStock / Immunicum’s Advancements with Ilixadencel
26 Feb 2020
Immunicum Article in BioStock
12 Feb 2020
RedEye Interview with COO, Sijme Zeilemaker
12 Feb 2020

See all

About us

Developing innovative cancer immunotherapies

Immunicum is advancing a novel cell-based approach to target solid tumors.

About

To top